KR101311061B1 - Ｌｉｆ 및 ｂｍｐ에 의한 종양 줄기 세포의 종양발생 가능성의 억제 - Google Patents

Ｌｉｆ 및 ｂｍｐ에 의한 종양 줄기 세포의 종양발생 가능성의 억제 Download PDF

Info

Publication number
KR101311061B1
KR101311061B1 KR1020127028173A KR20127028173A KR101311061B1 KR 101311061 B1 KR101311061 B1 KR 101311061B1 KR 1020127028173 A KR1020127028173 A KR 1020127028173A KR 20127028173 A KR20127028173 A KR 20127028173A KR 101311061 B1 KR101311061 B1 KR 101311061B1
Authority
KR
South Korea
Prior art keywords
cells
bmp
cell
target tumor
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020127028173A
Other languages
English (en)
Korean (ko)
Other versions
KR20120125990A (ko
Inventor
안젤로 뤼기 베스코비
브렌트 알랜 레이놀즈
Original Assignee
스템젠 에스.피.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스템젠 에스.피.에이. filed Critical 스템젠 에스.피.에이.
Publication of KR20120125990A publication Critical patent/KR20120125990A/ko
Application granted granted Critical
Publication of KR101311061B1 publication Critical patent/KR101311061B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2093—Leukaemia inhibitory factor [LIF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020127028173A 2005-07-19 2006-07-19 Ｌｉｆ 및 ｂｍｐ에 의한 종양 줄기 세포의 종양발생 가능성의 억제 Active KR101311061B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70085905P 2005-07-19 2005-07-19
US60/700,859 2005-07-19
PCT/IB2006/002296 WO2007010394A2 (en) 2005-07-19 2006-07-19 Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020087003552A Division KR101338533B1 (ko) 2005-07-19 2006-07-19 Ｌｉｆ 및 ｂｍｐ에 의한 종양 줄기 세포의 종양발생가능성의 억제

Publications (2)

Publication Number Publication Date
KR20120125990A KR20120125990A (ko) 2012-11-19
KR101311061B1 true KR101311061B1 (ko) 2013-09-25

Family

ID=37420973

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020087003552A Active KR101338533B1 (ko) 2005-07-19 2006-07-19 Ｌｉｆ 및 ｂｍｐ에 의한 종양 줄기 세포의 종양발생가능성의 억제
KR1020127028173A Active KR101311061B1 (ko) 2005-07-19 2006-07-19 Ｌｉｆ 및 ｂｍｐ에 의한 종양 줄기 세포의 종양발생 가능성의 억제

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020087003552A Active KR101338533B1 (ko) 2005-07-19 2006-07-19 Ｌｉｆ 및 ｂｍｐ에 의한 종양 줄기 세포의 종양발생가능성의 억제

Country Status (13)

Country Link
US (2) US9220756B2 (enExample)
EP (2) EP3117833B1 (enExample)
JP (3) JP5189977B2 (enExample)
KR (2) KR101338533B1 (enExample)
AU (1) AU2006271308B2 (enExample)
CA (2) CA2615491C (enExample)
DK (2) DK1904093T3 (enExample)
ES (2) ES2710601T3 (enExample)
HR (1) HRP20181379T1 (enExample)
HU (2) HUE040063T2 (enExample)
NZ (2) NZ565172A (enExample)
PL (2) PL3117833T3 (enExample)
WO (1) WO2007010394A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3117833T3 (pl) 2005-07-19 2019-06-28 Stemgen S.P.A. Hamowanie przez lif zdolności do tworzenia guzów przez komórki macierzyste guza
US8361955B2 (en) 2008-02-13 2013-01-29 Dkfz Deutsches Krebsforschungszentrum, Stiftung Des Offentlichen Rechts Methods for treating and preventing brain tumors based on bone morphogenetic proteins
IL298067A (en) 2015-08-25 2023-01-01 Histide Ag Compounds for inducing tissue formation and their uses
EP3998076A1 (en) * 2015-09-17 2022-05-18 Histide AG Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof
WO2017046226A2 (en) * 2015-09-17 2017-03-23 Histide Ag Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof.
KR20180050744A (ko) * 2015-09-17 2018-05-23 히스티드 아게 신생물성 세포를 비-신생물성 세포로 전환시키기 위한 약제학적 회합물 및 이것의 용도
WO2017046215A2 (en) * 2015-09-17 2017-03-23 Histide Ag Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof
WO2017046219A2 (en) * 2015-09-17 2017-03-23 Histide Ag Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof
US20220105122A1 (en) * 2018-12-28 2022-04-07 The University Of Tokyo Therapeutic and prophylactic agent for glioma, brain tumor malignancy marker, brain tumor prognostic marker, method for determining malignancy and prognosis of brain tumor and antibody inhibiting tumor proliferation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000029012A2 (en) * 1998-11-13 2000-05-25 Curis, Inc. Methods of alleviating cancer symptoms

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5324519A (en) * 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
GB9004890D0 (en) * 1990-03-05 1990-05-02 Heath John K Leukaemia inhibitory factor
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
DE69231726D1 (de) * 1991-12-24 2001-04-12 Amrad Corp Ltd Verwendung von leukämieinhibierendem faktor (lif) zur behandlung von tumoren und sarkomen
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US7592428B1 (en) * 1992-11-17 2009-09-22 Ludwig Institute For Cancer Research Antibodies which bind specifically to activin receptor like kinases
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
WO1995030003A2 (en) * 1994-04-29 1995-11-09 Creative Biomolecules, Inc. Morphogenic protein-specific cell surface receptors and uses therefor
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US6281015B1 (en) * 1994-12-16 2001-08-28 Children's Medical Center Corp. Localized delivery of factors enhancing survival of transplanted cells
US20010053371A1 (en) * 1999-01-07 2001-12-20 Waldemar Debinski Method for diagnosing, imaging, and treating tumors using restrictive receptor for interleukin 13
US5804162A (en) 1995-06-07 1998-09-08 Alliance Pharmaceutical Corp. Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
HUP9902418A3 (en) 1996-05-09 2001-10-29 Dimensional Pharm Inc Microplate thermal shift assay and apparatus for ligand development and multi-variable protein chemistry optimization
DE60030770T2 (de) * 1999-12-06 2007-09-06 Rhode Island Hospital Verwendung von taurolidin oder taurultam zur herstellung eines medikaments zur behandlung von ovarialkarzinomen
WO2001064239A1 (en) * 2000-03-03 2001-09-07 The Walter And Eliza Hall Institute Of Medical Research A method of treatment
JP4620052B2 (ja) 2003-09-12 2011-01-26 ステムセル テクノロジーズ インコーポレーティッド 神経コロニー形成アッセイ法
JP2005098727A (ja) 2003-09-22 2005-04-14 Hosiden Corp 振動センサ
EP1697715A4 (en) * 2003-12-05 2007-10-10 Univ Leland Stanford Junior IDENTIFICATION, ISOLATION AND ELIMINATION OF CANCER STEM CELLS
US8410246B2 (en) * 2004-06-17 2013-04-02 Thrasos, Inc. TDF-related compounds and analogs thereof
PL3117833T3 (pl) * 2005-07-19 2019-06-28 Stemgen S.P.A. Hamowanie przez lif zdolności do tworzenia guzów przez komórki macierzyste guza
ES2363358B1 (es) * 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
EP2371860A1 (en) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
JO3421B1 (ar) 2011-06-20 2019-10-20 H Lundbeck As طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية
US10130590B2 (en) * 2013-10-01 2018-11-20 Dana-Farber Cancer Institute, Inc. Methods of treating cancer with atovaquone-related compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000029012A2 (en) * 1998-11-13 2000-05-25 Curis, Inc. Methods of alleviating cancer symptoms

Also Published As

Publication number Publication date
ES2710601T3 (es) 2019-04-26
AU2006271308B2 (en) 2012-12-20
HRP20181379T1 (hr) 2018-11-16
NZ598031A (en) 2013-11-29
AU2006271308A1 (en) 2007-01-25
NZ565172A (en) 2012-12-21
US20100167999A1 (en) 2010-07-01
HUE040063T2 (hu) 2019-02-28
EP1904093B1 (en) 2018-06-13
PL3117833T3 (pl) 2019-06-28
CA2615491C (en) 2016-11-29
CA2790675C (en) 2016-12-20
EP1904093A2 (en) 2008-04-02
US20160228511A1 (en) 2016-08-11
ES2686093T3 (es) 2018-10-16
DK3117833T3 (en) 2019-03-18
JP2009502771A (ja) 2009-01-29
WO2007010394A2 (en) 2007-01-25
JP5891068B2 (ja) 2016-03-22
JP2015057452A (ja) 2015-03-26
EP3117833A1 (en) 2017-01-18
US9220756B2 (en) 2015-12-29
WO2007010394A3 (en) 2007-08-30
CA2790675A1 (en) 2007-01-25
HUE042197T2 (hu) 2019-06-28
DK1904093T3 (en) 2018-09-03
US9737589B2 (en) 2017-08-22
KR101338533B1 (ko) 2013-12-12
EP3117833B1 (en) 2019-01-23
KR20120125990A (ko) 2012-11-19
JP2012107063A (ja) 2012-06-07
PL1904093T3 (pl) 2018-12-31
CA2615491A1 (en) 2007-01-25
KR20080082595A (ko) 2008-09-11
JP5189977B2 (ja) 2013-04-24

Similar Documents

Publication Publication Date Title
US9737589B2 (en) Inhibition of the tumorigenic potential of tumor stem cells by LIF and BMPs
Lonardo et al. Pancreatic stellate cells form a niche for cancer stem cells and promote their self-renewal and invasiveness
Papachristou et al. Bone metastases: molecular mechanisms and novel therapeutic interventions
KR101719966B1 (ko) 종양 줄기세포에서 eph 수용체의 발현
Park et al. Combination treatment with VPA and MSCs-TRAIL could increase anti-tumor effects against intracranial glioma
Shi et al. Lysyl oxidase inhibition via β-aminoproprionitrile hampers human umbilical vein endothelial cell angiogenesis and migration in vitro
Mimeault et al. Complex Oncogenic Signaling Networks Regulate Brain Tumor‐Initiating Cells and Their Progenies: Pivotal Roles of Wild‐Type EGFR, EGFRvIII Mutant and Hedgehog Cascades and Novel Multitargeted Therapies
AU2012202157B2 (en) Inhibition of the tumorigenic potential of tumor stem cells by LIF and BMPS
HK1233494A (en) Inhibition of the tumorigenic potential of tumor stem cells by lif
HK1233494A1 (en) Inhibition of the tumorigenic potential of tumor stem cells by lif
HK1233494B (en) Inhibition of the tumorigenic potential of tumor stem cells by lif
HK1117414A (en) Inhibition of the tumorigenic potential of tumor stem cells by bmp-4
HK1117414B (en) Inhibition of the tumorigenic potential of tumor stem cells by bmp-4
Ponnazhagan Regenerative Stem Cell Therapy for Breast Cancer Bone Metastasis
SDA THE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1 MONOCLONAL ANTIBODY D16F7 INHIBITS GLIOMA GROWTH AND ANGIOGENESIS IN VIVO
Brun Molecular Regulators of Stem Cell Fate and Tumor Development in the Cerebellum
Salazar-Arcila Investigating the effects of CSF-1R and PI3Kdelta inhibition on a breast cancer bone metastasis model

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

FPAY Annual fee payment

Payment date: 20160818

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20170818

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20180816

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20190910

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 13

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 13